Unknown

Dataset Information

0

Tumor necrosis factor-alpha antagonist etanercept decreases blood pressure and protects the kidney in a mouse model of systemic lupus erythematosus.


ABSTRACT: Chronic inflammation has been implicated in the pathology of hypertension; however, the role for specific cytokines remains unclear. We tested whether tumor necrosis factor-? blockade with etanercept (Etan) reduces mean arterial pressure in a female mouse model of systemic lupus erythematosus (SLE). SLE is a chronic inflammatory disorder with prevalent hypertension. Thirty-week-old SLE (NZBWF1) and control mice (NZW/LacJ) received Etan (0.8 mg/kg SC weekly) for 4 weeks or vehicle. Mean arterial pressure (in millimeters of mercury) was increased in SLE mice (150±5 versus 113±5 in controls; P<0.05) and was lower in Etan-treated SLE mice (132±3) but not controls (117±5). Albuminuria (in micrograms per milligram of creatinine) was elevated in SLE mice (28 742±9032 versus 1075±883; P<0.05) and was lower in Etan-treated SLE mice (8154±3899) but not control animals (783±226). Glomerulosclerosis (in percentage of glomeruli) was evident in SLE mice (2.5±1.6 versus 0.0±0.0 in controls; P<0.05) and was ameliorated in Etan-treated SLE mice (0.1±0.1). Renal cortex CD68(+) cell staining (in percentage of area) was elevated in SLE mice (4.75±0.80 versus 0.79±0.12 in controls; P<0.05) and was lower in Etan-treated SLE mice (2.28±0.32) but not controls (1.43±0.25). Renal cortex NADPH oxidase activity (relative light units per milligram of protein) was higher in SLE mice compared with controls (10 718±1276 versus 7584±229; P<0.05) and lowered in Etan-treated SLE mice (6645±490). Renal cortex nuclear factor ?B (phosphorylated and nonphosphorylated) was increased in SLE mice compared with controls and lower in Etan-treated SLE mice. These data suggest that TNF-? mechanistically contributes to the development of hypertension in a chronic inflammatory disease through increased renal nuclear factor ?B, oxidative stress, and inflammation.

SUBMITTER: Venegas-Pont M 

PROVIDER: S-EPMC2989495 | biostudies-literature | 2010 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Tumor necrosis factor-alpha antagonist etanercept decreases blood pressure and protects the kidney in a mouse model of systemic lupus erythematosus.

Venegas-Pont Marcia M   Manigrasso Michaele B MB   Grifoni Samira C SC   LaMarca Babbette B BB   Maric Christine C   Racusen Lorraine C LC   Glover Porter H PH   Jones Allison V AV   Drummond Heather A HA   Ryan Michael J MJ  

Hypertension (Dallas, Tex. : 1979) 20100809 4


Chronic inflammation has been implicated in the pathology of hypertension; however, the role for specific cytokines remains unclear. We tested whether tumor necrosis factor-α blockade with etanercept (Etan) reduces mean arterial pressure in a female mouse model of systemic lupus erythematosus (SLE). SLE is a chronic inflammatory disorder with prevalent hypertension. Thirty-week-old SLE (NZBWF1) and control mice (NZW/LacJ) received Etan (0.8 mg/kg SC weekly) for 4 weeks or vehicle. Mean arterial  ...[more]

Similar Datasets

| S-EPMC9208548 | biostudies-literature
| S-EPMC2896914 | biostudies-literature
| S-EPMC2698614 | biostudies-literature
| S-EPMC1798099 | biostudies-literature
2014-06-03 | E-GEOD-46923 | biostudies-arrayexpress
| S-EPMC3446541 | biostudies-literature
2014-06-03 | GSE46923 | GEO
| S-EPMC3396783 | biostudies-literature
| S-EPMC1440614 | biostudies-literature
| S-EPMC2048842 | biostudies-literature